World-wide estimates put the number of individuals infected with hepatitis C virus (HCV) at over 170 million, with about one quarter in Greater China and about ten million in China. The market size and medical needs is large because of low screening rate, low consultation rate and high incidence.
With conventional HCV therapy, patients must suffer through the drugs' many side effects, including flu-like symptoms, fatigue and anemia. Current oral antiviral medication is too expensive to afford; the entrance of new drug will provide reasonable and affordable price to patients.
Furaprevir is a HCV protease inhibitor, discovered and developed in-house by TaiGen’s researchers. Through careful rational drug design with over 1,500 compounds synthesized and after extensive screening, Furaprevir was chosen for further development. Furaprevir has completed Phase I/II clinical trials in Taiwan under an US IND.
- Indications in Development
- Chronic Hepatitis C